| 摘要 |
<p>The present invention addresses the significant fraction of patients exposed to elevations in serotonergic neurotransmission, with or without concomitant changes in adrenergic neurotransmission, who do now and/or will in the future suffer degradation of treatment response with antidepressants. Along with decreased dopaminergic neurotransmission efficiency, the identification of certain psychiatric symptoms correlated with mood, reward and attentional dysfunctions may occur. Genetic profile in patients who are either not responsive to first line antidepressant medications or can remit to therapies targeting changes in serotonergic neurotransmission with or without concomitant changes in adrenergic neurotransmission for major depressive disorder.</p> |
